[Antiplatelet duration in the elderly patients after percutaneous coronary intervention]

Area of Science:

• Cardiology
• Geriatric Medicine
• Interventional Cardiology

Background:

• Ischemic heart disease is a major cause of mortality in Europe, with an aging population increasing the number of elderly patients undergoing procedures like percutaneous coronary intervention (PCI).
• Elderly patients face higher risks of bleeding and were underrepresented in major clinical trials, necessitating tailored treatment strategies.
• Dual antiplatelet therapy (DAPT) duration after PCI requires careful consideration due to increased risks in older individuals.

Purpose of the Study:

• To review hemorrhagic risk stratification and DAPT selection in elderly patients undergoing PCI.
• To discuss personalized DAPT duration based on individual bleeding and ischemic risk factors.
• To highlight the importance of updated European Society of Cardiology guidelines in managing DAPT in this demographic.

Main Methods:

• Literature review of current evidence and guidelines regarding DAPT in elderly patients post-PCI.
• Analysis of risk stratification tools for hemorrhagic and ischemic events.
• Discussion of DAPT duration modulation based on risk profiles and clinical scenarios.

Main Results:

• DAPT duration should be personalized, deviating from standard 6-12 month durations based on risk scores.
• Shorter DAPT (e.g., 1 month) is recommended for high bleeding risk patients, while longer durations may be considered for high ischemic risk.
• Newer drug-eluting stents allow for shorter DAPT durations safely; triple therapy necessitates shortest possible DAPT (e.g., 1 month).
• Proton pump inhibitors are essential for preventing gastrointestinal bleeding.

Conclusions:

• Personalized DAPT duration is paramount for elderly patients undergoing PCI, balancing ischemic protection with bleeding avoidance.
• Risk stratification tools and adherence to guidelines are essential for optimizing DAPT strategies in older adults.
• The use of advanced stent technology and appropriate pharmacotherapy, including proton pump inhibitors, improves safety and efficacy.